AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11275394
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's wort (3 tablets each containing 900 microg total hypericin, for 5 weeks)
Trial: 9395363
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (125 mg/day)
Trial: 9395363
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (250 mg/day)
Trial: 3555585
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg plus hydrochlorothiazide 25 mg, given twice daily for 1 month
Trial: 3555585
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg plus hydrochlorothiazide 25 mg, given once daily for 1 month
Trial: 3555585
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg plus hydrochlorothiazide 25 mg, given once or twice daily for 2 months
Trial: 31703750
Drug: Training therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training therapy
Trial: 28691640
Drug: n-3 supplements
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 supplements
Trial: 12826020
Drug: Sulphaphenazole (0.02-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphaphenazole (0.02-2 mg/min)
Trial: 12826020
Drug: Sulphaphenazole (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphaphenazole (6 mg/min) after L-NMMA (16 micromol/min) and ibuprofen (1200 mg, orally)
Trial: 12826020
Drug: L-NMMA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (4 micromol/min) and ibuprofen (1200 mg, orally)
Trial: 8925987
Drug: Short parenteral
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short parenteral treatment with antibiotics (exact dosage and duration not specified)
Trial: 8925987
Drug: Conventional long
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional long course treatment with antibiotics (exact dosage and duration not specified)
Trial: 6693780
Drug: Encapsulated liquid
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated liquid preparation of 8‐MOP
Trial: 30147307
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol (FP/SAL) 250/50 µg
Trial: 30147307
Drug: Tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide (TIO) 18 µg
Trial: 25821315
Drug: IFNα2a, RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNα2a, RBV and Q‐e‐I (5 g, orally, thrice daily in divided doses)
Trial: 24219376
Drug: 1.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/day of ResistAid
Trial: 24219376
Drug: 4.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 g/day of ResistAid
Trial: 19767527
Drug: Oral antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antioxidant (AO) cocktail (vitamins C and E and alpha-lipoic acid)
Trial: 11463595
Drug: NO inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO inhalation at 5 ppm in supine position (SP + NO)
Trial: 11463595
Drug: NO inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO inhalation in supine position (SP + NO) for Pu ARDS
Trial: 11463595
Drug: NO inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO inhalation in prone position (PP + NO) for Pu ARDS
Trial: 9529407
Drug: Active ultrasound
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ultrasound treatment (1 MHz, 1.0 W/cm2, pulsed mode 1:4, 15 minutes per session)
Trial: 27014353
Drug: Amlodipine/Valsartan 5/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/Valsartan 5/160 mg
Trial: 24762683
Drug: 7-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day triple regimen (rabeprazole 10 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 7 days)
Trial: 24762683
Drug: 10-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day triple regimen (rabeprazole 10 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days)
Trial: 24762683
Drug: 7-day quadruple
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day quadruple regimen (rabeprazole 10 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 7 days)
Trial: 24762683
Drug: 10-day quadruple
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day quadruple regimen (rabeprazole 10 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days)
Trial: 20142631
Drug: HOMA, QUICKI,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOMA, QUICKI, fasting glucose/insulin ratio, McAuley index
Trial: 10052877
Drug: Measured portal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measured portal dose images (PDIs) for lateral fields
Trial: 10052877
Drug: Measured portal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measured portal dose images (PDIs) for anterior fields
Trial: 10052877
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of measured and predicted portal doses for lateral fields
Trial: 10052877
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of measured and predicted portal doses for anterior fields
Trial: 10052877
Drug: Off-axis differences
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Off-axis differences in measured and predicted portal doses
Trial: 10052877
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of gas pockets during treatment
Trial: 7525185
Drug: Interferon (given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (given alone, in combination with conventional chemotherapy, or as maintenance therapy)
Trial: 7525185
Drug: Myelo-ablative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myelo-ablative therapy with autologous bone marrow transplantation (with or without in vitro treatment of the marrow)
Trial: 7525185
Drug: Radiolabelled monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiolabelled monoclonal antibodies
Trial: 7525185
Drug: Purine analogues
RxNorm normalized name: Purine analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purine analogues (e.g., fludarabine)
Trial: 26843588
Drug: MCCGA (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCCGA (400 mL coffee/d for 8 weeks; 420 mg CGA)
Trial: 26843588
Drug: HCCGA (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCCGA (400 mL coffee/d for 8 weeks; 780 mg CGA)
Trial: 24789057
Drug: DMAU 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMAU 200 mg with food
Trial: 24789057
Drug: DMAU 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMAU 800 mg with food
Trial: 24789057
Drug: DMAU 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMAU 800 mg fasting
Trial: 22447415
Drug: Desmopressin 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 10, 25, 50, or 100 µg
Trial: 21409314
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment (two daily injections)
Trial: 19216444
Drug: 0.1% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% bupivacaine continuous drip associated to fentanyl 2 lg/mL (CP‐group)
Trial: 10099740
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1.8g oral calcium daily)
Trial: 1351620
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination of the digestive tract (SDD) with amphotericin, colistin, and tobramycin applied to the oropharynx and enterally; all patients received intravenous cefotaxime for 72 hours.
Trial: 6731167
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment locations (group C, 116 strokes)
Trial: 16059622
Drug: No follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No follow-up treatment after teriparatide
Trial: 10740436
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg orally twice daily
Trial: 10740436
Drug: Pivampicillin 700
RxNorm normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin 700 mg orally twice daily
Trial: 2590265
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ibopamine
Trial: 2279257
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ibopamine + 40 mg furosemide
Trial: 31503332
Drug: Trabectedin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin (1.5 mg/m2)
Trial: 31503332
Drug: Dacarbazine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacarbazine (1 g/m2 over 20-120 minutes)
Trial: 28988962
Drug: Prehospital cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital cooling (surface ice packs, cold saline infusion, wristband reminders)
Trial: 23871731
Drug: More rapid
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More rapid intravenous fluid treatment
Trial: 23871731
Drug: Slower intravenous
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slower intravenous fluid treatment
Trial: 8484698
Drug: Adjuvant oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant oestrogen treatment
Trial: 21464154
Drug: Gemcitabine (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1250 mg/m2 on days 1 and 8) and cisplatin (75 mg/m2 on day 1)
Trial: 21464154
Drug: Gemcitabine (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1250 mg/m2 on days 1 and 8), cisplatin (75 mg/m2 on day 1), and PF-3512676 (0.2 mg/kg on days 8 and 15 of each chemotherapy cycle)
Trial: 19427432
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 to 40 mg/day
Trial: 18210954
Drug: Topical telbermin
RxNorm normalized name: Telbermin
DrugBank: Telbermin (DB12639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical telbermin (72 microg/cm2)
Trial: 8985850
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate solution (45 mL/1.7 m2/dose)
Trial: 8985850
Drug: Polyethylene glycol-based
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol-based solution (4 L/1.7 m2)
Trial: 6525441
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of prednisone as a reference solution or as a tablet in a 6‐week, six‐way crossover design
Trial: 6525441
Drug: Dissolution tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dissolution tests on five commercial tablet forms
Trial: 31551229
Drug: PICC catheter
RxNorm normalized name: STATLOCK PICC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PICC catheter parenteral nutrition support
Trial: 29270612
Drug: Direct therapy
RxNorm normalized name: Aleve Direct Therapy TENS Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct therapy for 8 to 12 weeks
Trial: 29270612
Drug: Indirect therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect therapy for 8 to 12 weeks
Trial: 18821106
Drug: Direct therapy
RxNorm normalized name: Aleve Direct Therapy TENS Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct therapy
Trial: 26818059
Drug: Titration PAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration PAP
Trial: 26818059
Drug: 6-week PAP
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week PAP therapy
Trial: 25579524
Drug: Electron beam
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electron beam therapy (16 Gy in 8 fractions)
Trial: 14698542
Drug: MVP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVP regimen (Mitomycin-C 8 mg/m2 d1, Vinblastine 4 mg/m2 d 1-8, Cisplatin 100 mg/m2 d1)
Trial: 14698542
Drug: MVC regimen
RxNorm normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVC regimen (Mitomycin-C 8 mg/m2 d1, Vinblastine 4 mg/m2 d 1-8, Carboplatin 300 mg/m2 d1)
Trial: 11533519
Drug: Buflomedil (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buflomedil (600 mg once daily) for 12 months
Trial: 9829381
Drug: Radioimmunoguided surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioimmunoguided surgery (RIGS) with Iodine‐125 labeled monoclonal antibodies (MoAbs) B72.3 anti‐TAG
Trial: 4929367
Drug: Azathioprine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2.5 mg/kg/day) and Prednisone (20 mg/day for adults, 0.5 mg/kg/day for children)
Trial: 28114993
Drug: Telephone interview
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone interview administration of the EuroQol Health Related Quality of Life survey
Trial: 28114993
Drug: Patient-completed form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-completed form administration of the EuroQol Health Related Quality of Life survey
Trial: 28114993
Drug: Both methods
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both methods of administration (telephone and patient-completed)
Trial: 23225897
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment in infants (IPTi) with sulfadoxine‐pyrimethamine (SP) administered at 2, 3, and 9 months of age
Trial: 16919749
Drug: Injected diacetylmorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected diacetylmorphine (DAM) plus oral methadone (average DAM dosage: 274.5 mg/day; average methadone dosage: 42.6 mg/day) for 9 months
Trial: 16919749
Drug: Oral methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methadone (average dosage: 105 mg/day) for 9 months
Trial: 15788738
Drug: Arginine supplementation
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine supplementation (8.5 g for 4 weeks)
Trial: 15788738
Drug: Isonitrogenous supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isonitrogenous supplement (control)
Trial: 7790242
Drug: Daily interfraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interfraction interval <= 4.5 h
Trial: 7790242
Drug: Daily interfraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interfraction interval > 4.5 h
Trial: 410053
Drug: DA antagonist
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA antagonist (droperidol)
Trial: 410053
Drug: ACh agonist
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACh agonist (physostigmine)
Trial: 19857081
Drug: Flavocoxid 250
RxNorm normalized name: FLAVOCOXID 250MG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavocoxid 250 mg twice a day
Trial: 17280748
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza vaccine with QS21 adjuvant
Trial: 17280748
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza vaccine without QS21 adjuvant
Trial: 11557467
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir (10 mg/kg every 8 h for 14 days) followed by oral acyclovir (800 mg q6h for 42 days)
Trial: 2842266
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) administered subcutaneously, 7,500 anti activated factor X Units once a day for 7 days
Trial: 2842266
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin (CH) administered subcutaneously, 5,000 International Units t.i.d. for 7 days
Trial: 31808656
Drug: Intravenous opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous opioid with 1 mg/kg tramadol HCl (Group O)
Trial: 30747501
Drug: Etanercept monotherapy
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept monotherapy (50 mg subcutaneous weekly)
Trial: 30747501
Drug: Methotrexate monotherapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate monotherapy (20 mg oral weekly)
Trial: 30747501
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Etanercept 50 mg subcutaneous weekly + Methotrexate 20 mg oral weekly)
Trial: 30747501
Drug: Etanercept monotherapy
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept monotherapy and Combination therapy
Trial: 28628970
Drug: Ankascin 568
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ankascin 568 (500 mg capsules, 2 capsules daily for 8 weeks)
Trial: 23281147
Drug: BTX‐A dilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTX‐A dilution of 100 U in 1 ml of saline (Group A)
Trial: 23281147
Drug: BTX‐A dilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTX‐A dilution of 100 U in 2 ml of saline (Group B)
Trial: 18972731
Drug: Chinese drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese drug
Trial: 12717239
Drug: mCsA (CsA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mCsA (CsA dose minimization)
Trial: 20093665
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AIT and ST (COM)
Trial: 16470490
Drug: Intravenous PD
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PD 123319 (10 mcg/minute for 5 minutes)
Trial: 7690383
Drug: Midodrine 10
RxNorm normalized name: midodrine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine 10 mg three times daily
Trial: 7690383
Drug: Midodrine 5
RxNorm normalized name: midodrine 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine 5 mg three times daily
Trial: 7690383
Drug: Midodrine 2.5
RxNorm normalized name: midodrine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine 2.5 mg three times daily
Trial: 3319543
Drug: All four
RxNorm normalized name: Jackson's The Original All Fours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All four drugs combined
Trial: 16418802
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) with observed viral load blips
Trial: 16418802
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) without observed viral load blips
Trial: 10856094
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m² (D100)
Trial: 9052337
Drug: t‐PA (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t‐PA (0.8 mg/kg, up to a maximum dose of 80 mg)
Trial: 9052337
Drug: Higher heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher heparin levels
Trial: 14735048
Drug: Heparin-coated circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuit (Duraflo II)
Trial: 26051095
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 600 mg for 12 weeks
Trial: 20601692
Drug: Maternal plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal plasma viral load >100,000 copies ml⁻¹